Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT
Open Access
- 17 March 2008
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 42 (1) , 67-69
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndromeLeukemia, 2007
- Immune hemolysis following ABO-mismatched stem cell or solid organ transplantationCurrent Opinion in Hematology, 2007
- Severe hemolytic anemia due to passenger lymphocytes after living‐related bowel transplantClinical Transplantation, 2004
- Rituximab for Immune Hemolytic Anemia following T- and B-Cell-Depleted Hematopoietic Stem Cell TransplantationActa Haematologica, 2002
- Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantationBone Marrow Transplantation, 2002
- Posttransplant immune‐mediated hemolysisTransfusion, 2002
- Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantationBone Marrow Transplantation, 1999
- Passenger B-lymphocyte-induced severe hemolytic disease after allogeneic peripheral blood stem cell transplantation [letter]Blood, 1996
- Hemolysis of transfused group O red blood cells in minor ABO-incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate.1992
- DONOR-DERIVED RED-BLOOD-CELL ANTIBODIES AND IMMUNE HEMOLYSIS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION1986